Partially Replacing Cyclophosphamide with Bendamustine in Combination with Cyclosporine A Improves Survival and Reduces Xenogeneic Graft-versus-host-disease

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Jan 26

PMID 36700195

Authors

Kristy E Gilman

Megan J Cracchiolo

Andrew P Matiatos

Dan W Davini

Richard J Simpson

Emmanuel Katsanis

Affiliations

Soon will be listed here.

Abstract

Introduction: The use of allogeneic hematopoietic cell transplantation (allo-HCT) for treating hematological disorders is increasing, but the development of graft-versus-host disease (GvHD) remains a major cause of morbidity and mortality. The use of post-transplant cyclophosphamide (CY) has significantly improved outcomes following allo-HCT, but complications of viral reactivation due to delayed immune reconstitution or relapse remain. Other laboratories are evaluating the potential benefit of lowering the dose of CY given post-transplant, whereas our laboratory has been focusing on whether partially replacing CY with another DNA alkylating agent, bendamustine (BEN) may be advantageous in improving outcomes with allo-HCT.

Methods: Here, we utilized a xenogeneic GvHD (xGvHD) model in which immunodeficient NSG mice are infused with human peripheral blood mononuclear cells (PBMCs).

Results: We show that a lower dose of CY (25 mg/kg) given on days +3 and +4 or CY (75 mg/kg) given on only day +3 post-PBMC infusion is not sufficient for improving survival from xGvHD, but can be improved with the addition of BEN (15 mg/kg) on day +4 to day +3 CY (75 mg/kg). CY/BEN treated mice when combined with cyclosporine A (CSA) (10mg/kg daily from days +5 to +18 and thrice weekly thereafter), had improved outcomes over CY/CY +CSA treated mice. Infiltration of GvHD target organs was reduced in both CY/CY and CY/BEN treatment groups versus those receiving no treatment. CY/CY +CSA mice exhibited more severe xGvHD at day 10, marked by decreased serum albumin and increased intestinal permeability. CY/BEN treated mice had reductions in naïve, effector memory and Th17 polarized T cells. RNAseq analysis of splenocytes isolated from CY/CY and CY/BEN treated animals revealed increased gene set enrichment in multiple KEGG pathways related to cell migration, proliferation/differentiation, and inflammatory pathways, among others with CY/BEN treatment.

Conclusion: Together, we illustrate that the use of CY/BEN is safe and shows similar control of xGvHD to CY/CY, but when combined with CSA, survival with CY/BEN is significantly prolonged compared to CY/CY.

Citing Articles

Comparative analysis of the effects of cyclophosphamide and dexamethasone on intestinal immunity and microbiota in delayed hypersensitivity mice.

Li X, Wen R, Chen B, Luo X, Li L, Ai J PLoS One. 2024; 19(10):e0312147.

PMID: 39418230 PMC: 11486373. DOI: 10.1371/journal.pone.0312147.

Post-Transplant Cyclophosphamide Combined with Brilliant Blue G Reduces Graft-versus-Host Disease without Compromising Graft-versus-Leukaemia Immunity in Humanised Mice.

Cuthbertson P, Button A, Sligar C, Elhage A, Vine K, Watson D Int J Mol Sci. 2024; 25(3).

PMID: 38339054 PMC: 10855770. DOI: 10.3390/ijms25031775.

References

Wu J, Jordan M, Waxman D . Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators. BMC Cancer. 2016; 16:623. PMC: 4982114. DOI: 10.1186/s12885-016-2597-2. View

Shi H, Hou B, Li H, Zhou H, Du B . Cyclophosphamide Induces the Ferroptosis of Tumor Cells Through Heme Oxygenase-1. Front Pharmacol. 2022; 13:839464. PMC: 8899725. DOI: 10.3389/fphar.2022.839464. View

Hilton J . Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Cancer Res. 1984; 44(11):5156-60. View

McCurdy S, Luznik L . How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide. Blood. 2019; 134(21):1802-1810. PMC: 6872960. DOI: 10.1182/blood.2019001323. View

Iclozan C, Yu Y, Liu C, Liang Y, Yi T, Anasetti C . T helper17 cells are sufficient but not necessary to induce acute graft-versus-host disease. Biol Blood Marrow Transplant. 2009; 16(2):170-8. PMC: 3876952. DOI: 10.1016/j.bbmt.2009.09.023. View

Wachsmuth L, Patterson M, Eckhaus M, Venzon D, Kanakry C . Optimized Timing of Post-Transplantation Cyclophosphamide in MHC-Haploidentical Murine Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019; 26(2):230-241. PMC: 7590501. DOI: 10.1016/j.bbmt.2019.09.030. View

Goldsmith S, Slade M, Dipersio J, Westervelt P, Lawrence S, Uy G . Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. Haematologica. 2016; 101(11):e465-e468. PMC: 5394884. DOI: 10.3324/haematol.2016.149880. View

Wang Y, Wu D, Liu Q, Xu L, Liu K, Zhang X . Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients. J Hematol Oncol. 2019; 12(1):88. PMC: 6724335. DOI: 10.1186/s13045-019-0781-y. View

Zeiser R, Blazar B . Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy. N Engl J Med. 2017; 377(22):2167-2179. PMC: 6034180. DOI: 10.1056/NEJMra1609337. View

10.

Briscoe J, Therond P . The mechanisms of Hedgehog signalling and its roles in development and disease. Nat Rev Mol Cell Biol. 2013; 14(7):416-29. DOI: 10.1038/nrm3598. View

11.

Stokes J, Hoffman E, Molina M, Eremija J, Larmonier N, Zeng Y . Bendamustine with Total Body Irradiation Limits Murine Graft-versus-Host Disease in Part Through Effects on Myeloid-Derived Suppressor Cells. Biol Blood Marrow Transplant. 2018; 25(3):405-416. PMC: 7571287. DOI: 10.1016/j.bbmt.2018.10.009. View

12.

Molina M, Hoffman E, Stokes J, Kummet N, Smith K, Baker F . Regulatory Dendritic Cells Induced by Bendamustine Are Associated With Enhanced Flt3 Expression and Alloreactive T-Cell Death. Front Immunol. 2021; 12:699128. PMC: 8264365. DOI: 10.3389/fimmu.2021.699128. View

13.

Khimani F, Ranspach P, Elmariah H, Kim J, Whiting J, Nishihori T . Increased Infections and Delayed CD4 T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation. Transplant Cell Ther. 2021; 27(11):940-948. DOI: 10.1016/j.jtct.2021.07.023. View

14.

Ehx G, Somja J, Warnatz H, Ritacco C, Hannon M, Delens L . Xenogeneic Graft-Versus-Host Disease in Humanized NSG and NSG-HLA-A2/HHD Mice. Front Immunol. 2018; 9:1943. PMC: 6125392. DOI: 10.3389/fimmu.2018.01943. View

15.

Gao Y, Shan W, Gu T, Zhang J, Wu Y, Li X . Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration. Front Immunol. 2022; 12:785774. PMC: 8720868. DOI: 10.3389/fimmu.2021.785774. View

16.

Hill G, Betts B, Tkachev V, Kean L, Blazar B . Current Concepts and Advances in Graft-Versus-Host Disease Immunology. Annu Rev Immunol. 2021; 39:19-49. PMC: 8085043. DOI: 10.1146/annurev-immunol-102119-073227. View

17.

Molina M, Stokes J, Hoffman E, Eremija J, Zeng Y, Simpson R . Bendamustine Conditioning Skews Murine Host DCs Toward Pre-cDC1s and Reduces GvHD Independently of Batf3. Front Immunol. 2020; 11:1410. PMC: 7378358. DOI: 10.3389/fimmu.2020.01410. View

18.

Soltermann Y, Heim D, Medinger M, Baldomero H, Halter J, Gerull S . Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study. Ann Hematol. 2019; 98(6):1485-1493. DOI: 10.1007/s00277-019-03673-3. View

19.

Strauss L, Czystowska M, Szajnik M, Mandapathil M, Whiteside T . Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin. PLoS One. 2009; 4(6):e5994. PMC: 2694984. DOI: 10.1371/journal.pone.0005994. View

20.

Styczynski J . Who Is the Patient at Risk of CMV Recurrence: A Review of the Current Scientific Evidence with a Focus on Hematopoietic Cell Transplantation. Infect Dis Ther. 2017; 7(1):1-16. PMC: 5840099. DOI: 10.1007/s40121-017-0180-z. View